Class comparison
SGLT2 inhibitors vs GLP-1 receptor agonists
Two of the most-prescribed diabetes drug classes in 2026. Different mechanisms, different strengths. Many patients with T2D + obesity + heart failure end up on both — they complement each other.
Head-to-head
| Factor | SGLT2 inhibitors | GLP-1 receptor agonists |
|---|---|---|
| Mechanism | Blocks SGLT2 cotransporter in kidney → glucose excreted in urine | Mimics gut hormone → satiety + slowed gastric emptying + insulin response |
| Administration | Once-daily oral pill | Once-weekly SC injection (oral semaglutide also exists) |
| A1C reduction | 0.5-1% | 1-2.4% |
| Weight loss | 2-3% (modest) | 15-21% on max-dose Wegovy/Zepbound |
| Cardiovascular benefit | Heart failure + CKD progression reduction (proven) | MACE reduction in CVD + obesity (Wegovy, 2024) |
| Major side effects | Genital yeast infections (~5%), euglycemic DKA (rare), volume depletion | GI (nausea 44%, vomiting 24%, constipation 24%) |
| Typical cost (cash) | $500-700/mo | $968-1,199/mo brand |
When SGLT2 is preferred
- • Patients with heart failure (HFpEF or HFrEF) — SGLT2 has Class IA recommendation.
- • Patients with chronic kidney disease — eGFR decline slows on SGLT2.
- • Patients who cannot tolerate or refuse weekly injection.
- • Patients on metformin with mild hyperglycemia and no obesity priority.
When GLP-1 is preferred
- • Patients with T2D + obesity — weight loss is the dominant goal.
- • Patients with established atherosclerotic CVD — Wegovy MACE reduction.
- • Patients with NAFLD/MASH — emerging benefit from tirzepatide.
- • Patients with OSA + obesity — Zepbound is FDA-approved (2024).
Combination therapy
For T2D + obesity + CVD, ADA 2024 Standards of Care endorse combining a GLP-1 with an SGLT2 inhibitor. The two classes are mechanistically complementary — GLP-1 drives satiety and weight loss; SGLT2 protects the heart and kidneys. Monitor for additive hypoglycemia risk if insulin or sulfonylureas are also on board.